EDAP TMS S.A. to Release 2006 First Quarter Financial Results May 10, 2006
May 09 2006 - 9:00AM
PR Newswire (US)
LYON, France, May 4 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), will release its first quarter financial results for
the period ending March 31, 2006 on Wednesday, May 10, 2006 after
the market close. The company will host a conference call to
discuss the results and answer questions from investors on
Thursday, May 11, 2006, at noon Eastern Time, 6:00 p.m. Paris Time.
Representing the Company on the call will be Philippe Chauveau,
Chairman of the Board, Hugues de Bantel, Chief Executive Officer,
and Thierry Turbant, Chief Financial Officer. Interested investors
may join the call live by dialing (866) 200-5830 from the United
States or +1 (732) 694-1588 from international locations and
entering PIN code 558429#. Investors may also listen to the live
call online at http://www.edap-tms.com/ . Investors unable to join
the call can access a playback of the conference call by telephone
or online. To access the replay, please dial (866) 206-0173 or +1
(732) 694-1571 and using access code 173563# beginning one hour
after the end of the call until May 18, 2006, or visit the
company's Web site at http://www.edap-tms.com/ . About EDAP TMS
S.A. EDAP TMS S.A. develops and markets Ablatherm, the most
advanced and clinically proven choice for High Intensity Focused
Ultrasound (HIFU) treatment of localized prostate cancer. HIFU
treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized
prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option or patients who failed
radiotherapy treatment. The company is also developing this
technology for the treatment of certain other types of tumors. EDAP
TMS S.A. also produces and commercializes medical equipment for
treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL). For more information on the Company, contact
Halliburton Investor Relations at (972) 458-8000, the Corporate
Investor Relations Dept at +33 (0)4 78 26 40 46 or see the
Company's Web sites at http://www.edap-tms.com/ and
http://www.hifu-planet.com/ . This press release contains, in
addition to historical information, forward-looking statements that
involve risks and uncertainties. These include statements regarding
the Company's growth and expansion plans. Such statements are based
on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. Ablatherm-HIFU treatment is in
clinical trials but not yet FDA approved or marketed in the United
States. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe Chauveau
Blandine Confort +33 4 78 26 40 46 Halliburton Investor Relations
Matt Kreps - Geralyn DeBusk 972 458 8000 DATASOURCE: EDAP TMS S.A.
CONTACT: Hugues de Bantel, or Philippe Chauveau, or Blandine
Confort, all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or
Geralyn DeBusk, both of Halliburton Investor Relations,
+1-972-458-8000, for EDAP TMS S.A. Web site:
http://www.edap-tms.com/ http://www.hifu-planet.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024